Latest topics page 39

Topics ordered by most recent activity across all 71 subcategories.

1,535 topics · page 39 of 52

Topic	Participants	Replies	Views	Activity
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists Compounds › Cagrilintide & amylin analogues effect size cagrilintide cagrisema amylin analogues Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with FLOW ( N Engl…	+48	53	31k	13mo
Anxiety in the first weeks: drug, situation, or both Wellbeing › Mental health disordered eating beginner friendly mood On the subject in the title: Anxiety in the first weeks: drug, situation, or both Working notes rather than a conclusion. General question, not a request for advice about my own care — I know the difference…	+104	114	1.4k	13mo
[2026 update] Documentation that materially improves an appeal's chances Access › Insurance & coverage prior authorisation formulary appeals On the subject in the title: Documentation that materially improves an appeal's chances Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…		2	2.4k	13mo
Revisiting: Food effects on oral incretin absorption: what is documented Compounds › Oral incretins oral semaglutide PIONEER programme SOUL trial orforglipron Under review Revisiting: Food effects on oral incretin absorption: what is documented — setting out what I have, and where I think it stops being reliable. Session topic: SURMOUNT-2 ( Lancet , 2023). Please read it before…	+6	10	51k	13mo
Reading a chromatogram someone posted without axes Analytics › HPLC & UHPLC HPLC UV & DAD detection gradient method data table Reading a chromatogram someone posted without axes — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a certificate in front…	+47	55	9.4k	13mo
Random versus fixed effects: choosing rather than defaulting Evidence › Meta-analyses effect size publication bias risk of bias heterogeneity Closed Random versus fixed effects: choosing rather than defaulting — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before posting;…	+16	20	22k	13mo
Coming back to: Why semaglutide solutions can look faintly opalescent and when that matters Compounds › Semaglutide SELECT trial randomised trial STEP programme Asking directly, because I could not find a straight answer: Why semaglutide solutions can look faintly opalescent and when that matters Comparing SELECT ( N Engl J Med , 2023) with PIONEER 6 ( N Engl J Med ,…	+16	20	17k	13mo
Pen wastage and its effect on real cost — the long version Access › Pricing formulary data table cost per milligram compounding Posting this under the heading it deserves: Pen wastage and its effect on real cost — the long version Everything below is what sits behind that. Documenting an access outcome, dated, because everything in…		2	34k	13mo
Request declined, with reasoning Meta › Feature requests site feedback translation wiki post Wiki Request declined, with reasoning — setting out what I have, and where I think it stops being reliable. Process question about how this site works. I have read the guidelines and the trust-level page and I…	+2	6	173	13mo
Payment mechanics and the recovery options that do not exist — what changed since Sourcing › Payments documentation quality payments research use only Solved On the subject in the title: Payment mechanics and the recovery options that do not exist — what changed since Working notes rather than a conclusion. A logistics question, since the answers here are usually…	+14	18	17k	13mo
Why plausible mechanism is not evidence of effect — one year on Compounds › Repair & healing peptides needs a source preprint BPC-157 Solved Closed The question in the title: Why plausible mechanism is not evidence of effect — one year on I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read…	+3	7	3.6k	13mo
Hepatic steatosis: what the MASH trial evidence supports Clinical › Comorbidities MASH / hepatic steatosis PCOS type 2 diabetes chronic kidney disease Hepatic steatosis: what the MASH trial evidence supports — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published trials in…	+77	83	950	13mo
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Evidence › Journal club randomised trial risk of bias effect size estimand Posting this under the heading it deserves: Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with FLOW…	+58	64	17k	13mo
Interim analyses and stopping rules — does this still hold? Evidence › Trials estimand discontinuation & dropout open label surrogate endpoints Solved Interim analyses and stopping rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N Engl J Med , 2015) with SURMOUNT-4 (…	+30	34	29k	13mo
Whether an aggregate is worth publishing at all: a disputed topic Data & Tools › Datasets confounding site feedback observational data On the subject in the title: Whether an aggregate is worth publishing at all: a disputed topic Working notes rather than a conclusion. I would like to understand what this number means before I repeat it…	+20	24	18k	13mo
Vagal afferents and the gut-brain pathway Pharmacology › Receptor biology semaglutide tirzepatide retatrutide long read On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front of me that…	+5	9	44k	13mo
Repeatability versus intermediate precision Analytics › Method validation precision & repeatability recovery LOD & LOQ linearity Solved Repeatability versus intermediate precision — setting out what I have, and where I think it stops being reliable. Posting the method first, because I know what the first three replies will otherwise be.…	+119	134	34k	13mo
Coming back to: Why the cheapest option is often not the cheapest Access › Pricing formulary cost per milligram data table compounding Why the cheapest option is often not the cheapest — that is the question, and I have not found it answered plainly anywhere I have looked. Documenting an access outcome, dated, because everything in this…	+21	25	55k	13mo
Why plausible mechanism is not evidence of effect Compounds › Repair & healing peptides TB-500 preprint observational data Solved Closed Asking directly, because I could not find a straight answer: Why plausible mechanism is not evidence of effect Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the discussion is much…	+14	18	57k	13mo
Reading a regulatory notice rather than an article about it — what changed since Sourcing › Regulatory research use only MHRA FDA personal import Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually…	+28	32	640	13mo
Severe gastroparesis and why this class is a poor fit Safety › Contraindications pancreatitis pregnancy & planning delayed gastric emptying Solved On the subject in the title: Severe gastroparesis and why this class is a poor fit Working notes rather than a conclusion. Asking about a population rather than about a person. The published trials in this…		3	62k	13mo
A report I filed that turned out to be wrong, and the correction Sourcing › Vendor reports certificate of analysis disputed third-party testing A report I filed that turned out to be wrong, and the correction Writing it up because I had to work it out twice and would rather nobody else did. Structured report rather than an opinion, following the…	+124	132	12k	13mo
A friction point in the promotion workflow — the long version Meta › Site feedback moderation site feedback guidelines On the subject in the title: A friction point in the promotion workflow — the long version Working notes rather than a conclusion. Nominating something for promotion into the documentation commons. The topic…	+1	5	46k	13mo
Mood changes: monitoring, and when to involve a professional Wellbeing › Mental health mood beginner friendly disordered eating Mood changes: monitoring, and when to involve a professional — setting out what I have, and where I think it stops being reliable. General question, not a request for advice about my own care — I know the…		2	362	13mo
Obstructive sleep apnoea and a hard endpoint in this class Clinical › Comorbidities chronic kidney disease PCOS obstructive sleep apnoea blood pressure On the subject in the title: Obstructive sleep apnoea and a hard endpoint in this class Working notes rather than a conclusion. Asking about a population rather than about a person. The published trials in…	+120	129	1.8k	13mo
Journal club: STEP 4 and what a withdrawal design can prove Evidence › Journal club randomised trial risk of bias effect size Solved On the subject in the title: Journal club: STEP 4 and what a withdrawal design can prove Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…	+61	65	2k	13mo
Amylin analogue mechanism: satiety signalling separate from GLP-1 Compounds › Cagrilintide & amylin analogues effect size randomised trial cagrilintide cagrisema Solved Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SCALE ( N Engl J Med , 2015) and…	+128	142	38k	13mo
Second pass at: Semaglutide and alcohol: what is actually documented Compounds › Semaglutide semaglutide type 2 diabetes effect size randomised trial Closed Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…	+15	19	4.4k	13mo
Second pass at: How to research a compound with no human data without deceiving yourself Compounds › Other compounds research use only custom synthesis needs a source mislabelling Second pass at: How to research a compound with no human data without deceiving yourself Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med ,…	+64	71	2.5k	13mo
[2026 update] Clearance pathways and what renal impairment changes Pharmacology › Pharmacokinetics missed dose liraglutide worked example Solved On the subject in the title: Clearance pathways and what renal impairment changes Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front…	+63	69	50k	13mo